Lucía Prieto-Torres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lucía Prieto-Torres has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Luis Requena
Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
6 shared publications- Javier Sánchez-Bernal
Servicio de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España
3 shared publications - Luis Requena
Department of Dermatology Hospital Universitario Fundación Jiménez Díaz Madrid Spain
3 shared publications - Mar García-García
Faculty of Medicine University of Zaragoza Zaragoza Spain
3 shared publications Lorenzo Cerroni
Research Unit of Dermatopathology Medical University of Graz Graz Austria
2 shared publicationsM. Ara Martín
Servicio de Dermatología, Hospital Clínico Lozano Blesa, Zaragoza, España
2 shared publications
Latest Publications
- 31 August 2026
- Published by Wiley in Australasian Journal of Dermatology
Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma With Unusual Clinicopathological Characteristics: A Study of Three Patients With Molecular Characterization
Primary cutaneous gamma‐delta T‐cell lymphoma (PCGDTCL) is a rare cytotoxic lymphoma with considerable clinicopathological heterogeneity. We report three patients with unusual presentations, including a TCR‐silent phenotype with spontaneous regression followed by rapid progression, a granulomatous variant with a prolonged indolent course, and a lupus panniculitis‐like form. Molecular studies demonstrated persistent clonal disease and identified recurrent alterations involving TET2 , STAT3 , CDKN2A , MAPK1 , PDCD1 and TNFAIP3 , with acquisition of additional mutations during disease evolution. These cases expand the recognized spectrum of PCGDTCL and highlight the importance of integrating clinicopathological and molecular findings in diagnostically challenging presentations.
- 31 August 2026
- Published by Wiley in Australasian Journal of Dermatology
Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma With Unusual Clinicopathological Characteristics: A Study of Three Patients With Molecular Characterization
Primary cutaneous gamma‐delta T‐cell lymphoma (PCGDTCL) is a rare cytotoxic lymphoma with considerable clinicopathological heterogeneity. We report three patients with unusual presentations, including a TCR‐silent phenotype with spontaneous regression followed by rapid progression, a granulomatous variant with a prolonged indolent course, and a lupus panniculitis‐like form. Molecular studies demonstrated persistent clonal disease and identified recurrent alterations involving TET2 , STAT3 , CDKN2A , MAPK1 , PDCD1 and TNFAIP3 , with acquisition of additional mutations during disease evolution. These cases expand the recognized spectrum of PCGDTCL and highlight the importance of integrating clinicopathological and molecular findings in diagnostically challenging presentations.
- 24 February 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (2) , 103469
Aureobasidium melanogenum as an unexpected cause of facial hyperpigmentation in a young immunocompetent man
- 24 February 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (2) , 103469
Aureobasidium melanogenum as an unexpected cause of facial hyperpigmentation in a young immunocompetent man
- 17 February 2026
- Published by Elsevier in Medicina de Familia. SEMERGEN
- Vol. 52 (3) , 102720
Psoriasis moderada-grave y comorbilidad asociada en pacientes en tratamiento biológico: implicaciones para atención primaria
- 17 February 2026
- Published by Elsevier in Medicina de Familia. SEMERGEN
- Vol. 52 (3) , 102720
Psoriasis moderada-grave y comorbilidad asociada en pacientes en tratamiento biológico: implicaciones para atención primaria
- Open Access
- 22 May 2025
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 18
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals. Interleukin (IL)-17 and IL-23 inhibitors may have beneficial effects on MASLD by reducing systemic inflammation and improving metabolic parameters. Objectives: To assess the effect of IL-17 and IL-23 inhibitors on MASLD and liver fibrosis in patients with psoriasis. Design: We performed a systematic review that followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Data sources and methods: A literature search was conducted across four databases: MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials, from database inception to September 27, 2024. Observational studies and clinical trials that reported the presence of MASLD and/or liver fibrosis in patients with psoriasis/psoriatic arthritis treated with IL-17 or IL-23 inhibitors were included. The Newcastle Ottawa Scale (NOS) was used for risk of bias assessment in cohort studies, the Revised Cochrane Risk of Bias Tool (RoB2.0) in randomized controlled trials, and the Risk of Bias in non-randomized studies-of Interventions (ROBINS-I v.2) tool in non-randomized trials. Results: Fourteen studies were included: four clinical trials, five retrospective cohort studies, three prospective cohort studies, and two post hoc studies. Two cohort studies and one clinical trial showed a low risk of bias. Both post hoc studies had a high risk of bias. Eleven studies assessed the effect of IL-17 inhibitors on MASLD or liver fibrosis; six reported a neutral effect, while five demonstrated improvements in liver tests. Three studies evaluated IL-23 inhibitors; one showed neutral effects, another reported improvement in fibrosis-4 index (FIB-4) scores at 6 months, and the third was still in the recruitment phase. Conclusion: IL-17 and IL-23 inhibitors may provide beneficial effects on MASLD and liver fibrosis in patients with psoriasis. Larger, well-designed studies are needed to confirm these findings. Trial registration: PROSPERO CRD42024599350.
- 22 May 2025
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 18
Open AccessMASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals. Interleukin (IL)-17 and IL-23 inhibitors may have beneficial effects on MASLD by reducing systemic inflammation and improving metabolic parameters. Objectives: To assess the effect of IL-17 and IL-23 inhibitors on MASLD and liver fibrosis in patients with psoriasis. Design: We performed a systematic review that followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Data sources and methods: A literature search was conducted across four databases: MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials, from database inception to September 27, 2024. Observational studies and clinical trials that reported the presence of MASLD and/or liver fibrosis in patients with psoriasis/psoriatic arthritis treated with IL-17 or IL-23 inhibitors were included. The Newcastle Ottawa Scale (NOS) was used for risk of bias assessment in cohort studies, the Revised Cochrane Risk of Bias Tool (RoB2.0) in randomized controlled trials, and the Risk of Bias in non-randomized studies-of Interventions (ROBINS-I v.2) tool in non-randomized trials. Results: Fourteen studies were included: four clinical trials, five retrospective cohort studies, three prospective cohort studies, and two post hoc studies. Two cohort studies and one clinical trial showed a low risk of bias. Both post hoc studies had a high risk of bias. Eleven studies assessed the effect of IL-17 inhibitors on MASLD or liver fibrosis; six reported a neutral effect, while five demonstrated improvements in liver tests. Three studies evaluated IL-23 inhibitors; one showed neutral effects, another reported improvement in fibrosis-4 index (FIB-4) scores at 6 months, and the third was still in the recruitment phase. Conclusion: IL-17 and IL-23 inhibitors may provide beneficial effects on MASLD and liver fibrosis in patients with psoriasis. Larger, well-designed studies are needed to confirm these findings. Trial registration: PROSPERO CRD42024599350.
- Open Access
- 10 February 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (4) , T378-T393
[Translated article] An Update on EBV-related Cutaneous Lymphoproliferative Disorders: a Systematic Review
- 10 February 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (4) , T378-T393
Open Access[Translated article] An Update on EBV-related Cutaneous Lymphoproliferative Disorders: a Systematic Review
- Open Access
- 13 November 2024
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (4) , 378-393
Actualización en procesos linfoproliferativos cutáneos relacionados con el virus de Epstein Barr: revisión sistemática
- 13 November 2024
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (4) , 378-393
Open AccessActualización en procesos linfoproliferativos cutáneos relacionados con el virus de Epstein Barr: revisión sistemática
- 6 June 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (11) , 1605-1606
Tralokinumab‐related facial redness: a therapeutic challenge
- 6 June 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (11) , 1605-1606
Tralokinumab‐related facial redness: a therapeutic challenge
- 6 May 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 51 (8) , 598-603
Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review
Traditionally, skin involvement in chronic myelomonocytic leukemia (CMML) has been considered to be either specific (leukemia cutis) or non‐specific, with granulomatous dermatitis included in the latter group. More recently, the true nature of the myeloid cells present in the cutaneous infiltrates of this theoretically reactive dermatitis is being clarified with the use of new molecular techniques such as next‐generation sequencing. The same mutations in bone marrow (BM) myeloid neoplastic cells and in the cells of cutaneous infiltrates have been found. We present the case of a 77‐year‐old man who presented with spread and treatment‐resistant skin granulomatous lesions previous to the diagnosis of CMML. The same clonal mutations in SRSF2, IDH1, and RUNX1 were found in both skin and BM with resolution of the lesions after the initiation of azacytidine. In conclusion, we report an exceptional case in which specific granulomatous cutaneous lesions have preceded and allowed the earlier diagnosis of an underlying CMML and a review of all previous similar cases in the literature, including molecular alterations.
- 6 May 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 51 (8) , 598-603
Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review
Traditionally, skin involvement in chronic myelomonocytic leukemia (CMML) has been considered to be either specific (leukemia cutis) or non‐specific, with granulomatous dermatitis included in the latter group. More recently, the true nature of the myeloid cells present in the cutaneous infiltrates of this theoretically reactive dermatitis is being clarified with the use of new molecular techniques such as next‐generation sequencing. The same mutations in bone marrow (BM) myeloid neoplastic cells and in the cells of cutaneous infiltrates have been found. We present the case of a 77‐year‐old man who presented with spread and treatment‐resistant skin granulomatous lesions previous to the diagnosis of CMML. The same clonal mutations in SRSF2, IDH1, and RUNX1 were found in both skin and BM with resolution of the lesions after the initiation of azacytidine. In conclusion, we report an exceptional case in which specific granulomatous cutaneous lesions have preceded and allowed the earlier diagnosis of an underlying CMML and a review of all previous similar cases in the literature, including molecular alterations.
- Open Access
Clinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): An Integrative Review
Myeloid neoplasms and acute leukemias include different entities that have been recently re-classified taking into account molecular and clinicopathological features. The myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) category comprises a heterogeneous group of hybrid neoplastic myeloid diseases characterized by the co-occurrence of clinical and pathological features of both myelodysplastic and myeloproliferative neoplasms. The most frequent entity in this category is chronic myelomonocytic leukemia (CMML) which is, after acute myeloid leukemia (AML), the main myeloid disorder prone to develop cutaneous manifestations. Skin lesions associated with myelodysplastic and myeloproliferative neoplasms include a broad clinical, histopathological and molecular spectrum of lesions, poorly understood and without a clear-cut classification in the current medical literature. The aim of this review is to describe and classify the main clinical, histopathological and molecular patterns of cutaneous lesions in the setting of MDS/MPN in order to improve the diagnostic skills of the dermatologists, hematologists and pathologists who deal with these patients.
Open AccessClinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): An Integrative Review
Myeloid neoplasms and acute leukemias include different entities that have been recently re-classified taking into account molecular and clinicopathological features. The myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) category comprises a heterogeneous group of hybrid neoplastic myeloid diseases characterized by the co-occurrence of clinical and pathological features of both myelodysplastic and myeloproliferative neoplasms. The most frequent entity in this category is chronic myelomonocytic leukemia (CMML) which is, after acute myeloid leukemia (AML), the main myeloid disorder prone to develop cutaneous manifestations. Skin lesions associated with myelodysplastic and myeloproliferative neoplasms include a broad clinical, histopathological and molecular spectrum of lesions, poorly understood and without a clear-cut classification in the current medical literature. The aim of this review is to describe and classify the main clinical, histopathological and molecular patterns of cutaneous lesions in the setting of MDS/MPN in order to improve the diagnostic skills of the dermatologists, hematologists and pathologists who deal with these patients.
- Open Access
- 13 November 2023
- Published by MDPI AG in Preprints.org
Clinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): A Review and A Proposed Classification
Myeloid neoplasms and acute leukemias include different entities that have been recently re-classify taking into account molecular and clinicopathological features. The myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) category comprises a heterogeneous group of hybrid neoplastic myeloid diseases characterized by the co-occurrence of clinical and pathologic features of both myelodysplastic and myeloproliferative neoplasms. The most frequent entity in this category is chronic myelomonocytic leukemia (CMML) which is, after acute myeloid leukemia (AML), the main myeloid disorder prone to develop cutaneous manifestations. Skin lesions associated with myelodysplastic and myeloproliferative neoplasms include a broad clinical, histopathological and molecular spectrum of lesions, poorly understood and without a clear-cut classification in the current medical literature. The aim of this review is to describe and classify the main clinical, histopathological and molecular patterns of cutaneous lesions in the setting of MDS/MPN in order to improve the diagnostic skills of dermatologists, hematologist and pathologist who deal with these patients.
- 13 November 2023
- Published by MDPI AG in Preprints.org
Open AccessClinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): A Review and A Proposed Classification
Myeloid neoplasms and acute leukemias include different entities that have been recently re-classify taking into account molecular and clinicopathological features. The myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) category comprises a heterogeneous group of hybrid neoplastic myeloid diseases characterized by the co-occurrence of clinical and pathologic features of both myelodysplastic and myeloproliferative neoplasms. The most frequent entity in this category is chronic myelomonocytic leukemia (CMML) which is, after acute myeloid leukemia (AML), the main myeloid disorder prone to develop cutaneous manifestations. Skin lesions associated with myelodysplastic and myeloproliferative neoplasms include a broad clinical, histopathological and molecular spectrum of lesions, poorly understood and without a clear-cut classification in the current medical literature. The aim of this review is to describe and classify the main clinical, histopathological and molecular patterns of cutaneous lesions in the setting of MDS/MPN in order to improve the diagnostic skills of dermatologists, hematologist and pathologist who deal with these patients.